EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes

Jordan S Sherwood, Luz E Castellanos, Mollie Y O'Connor, Courtney A Balliro, Mallory A Hillard, Sarah Grace Gaston, Rachel Bartholomew, Evelyn Greaux, Amy Sabean, Hui Zheng, Peter Marchetti, Ahmet Uluer und 6 weitere

Diabetes Care · 2024

DOI: 10.2337/dc23-1411 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Jordan S Sherwood und 17 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Center, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Cystic Fibrosis, Hypoglycemia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Cystic Fibrosis Foundation, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Cystic fibrosis–related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis and adds significant morbidity and treatment burden. We evaluated the safety and efficacy of automated insulin delivery with the iLet bionic pancreas (BP) in adults with CFRD in a single-center, open-label, random-order, crossover trial. RESEARCH DESIGN AND METHODS Twenty participants with CFRD were assigned in random order to 14 days each on the BP or their usual care (UC). No restrictions were placed on diet or activity. The primary outcome was the percent time sensor-measured glucose was in target range 70–180 mg/dL (time in range [TIR]) on days 3–14 of each arm, and key secondary outcomes included mean continuous glucose monitoring (CGM) glucose and the percent time sensor-measured glucose was in hypoglycemic range <54 mg/dL. RESULTS TIR was significantly higher in the BP arm than the UC arm (75 ± 11% vs. 62 ± 22%, P = 0.001). Mean CGM glucose was lower in the BP arm than in the UC arm (150 ± 19 vs. 171 ± 45 mg/dL, P = 0.007). There was no significant difference in percent time with sensor-measured glucose <54 mg/dL (0.27% vs. 0.36%, P = 1.0), although self-reported symptomatic hypoglycemia episodes were higher during the BP arm than the UC arm (0.7 vs. 0.4 median episodes per day, P = 0.01). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either arm. CONCLUSIONS Adults with CFRD had improved glucose control without an increase in CGM-measured hypoglycemia with the BP compared with their UC, suggesting that this may be an important therapeutic option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Cystic FibrosisHypoglycemiaAdultHumansInsulinBlood Glucose Self-MonitoringBionicsBlood GlucoseInsulin Infusion SystemsHypoglycemic AgentsInsulin, Regular, HumanPancreas

Substanzen

InsulinBlood GlucoseHypoglycemic AgentsInsulin, Regular, Human

Autor:innen und Institutionen

  • Diabetes Research Center, Massachusetts General Hospital, Boston, MA.
  • Beta Bionics Inc., Concord, MA.
  • Biostatics Center, Massachusetts General Hospital, Boston, MA.
  • Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA.
  • Division of Pulmonology, Brigham and Women's Hospital, Boston, MA.
  • Division of Pulmonology and Critical Care, Massachusetts General Hospital, Boston, MA.

ORCID-Profile: Melissa S Putman

Förderung

  • NIDDK NIH HHS
  • Cystic Fibrosis Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Sherwood, J. S., Castellanos, L. E., O'Connor, M. Y., Balliro, C. A., Hillard, M. A., Gaston, S. G., Bartholomew, R., Greaux, E., Sabean, A., Zheng, H., Marchetti, P., Uluer, A., Sawicki, G. S., Neuringer, I., El-Khatib, F. H., Damiano, E. R., Russell, S. J., & Putman, M. S. (2024). Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes. Diabetes Care. https://doi.org/10.2337/dc23-1411

Vancouver

Sherwood JS, Castellanos LE, O'Connor MY, Balliro CA, Hillard MA, Gaston SG, et al. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes. Diabetes Care. 2024. doi:10.2337/dc23-1411

BibTeX
@article{Sherwood2024,
  author = {Sherwood, Jordan S and Castellanos, Luz E and O'Connor, Mollie Y and Balliro, Courtney A and Hillard, Mallory A and Gaston, Sarah Grace and Bartholomew, Rachel and Greaux, Evelyn and Sabean, Amy and Zheng, Hui and Marchetti, Peter and Uluer, Ahmet and Sawicki, Gregory S and Neuringer, Isabel and El-Khatib, Firas H and Damiano, Edward R and Russell, Steven J and Putman, Melissa S},
  title = {Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-1411}
}
Kostenlos starten →